Adkinson Jr NF, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler JD, Updyke L, Shear NH, Wierda D (2002). Task force report: future research needs for prevention and management of immune-mediated drug hypersensitivity reactions. J. Allergy Clin. Immunol. 109(3):461-478.
Crossref

Alerhand S, Cassella C, Koyfman A (2016). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Pediatric Population: A Review. Pediatr. Emerg. Care 32(7):472-476.
Crossref

Andreoli MX, Tellez M, Guglielmone A, Velásquez CM, Dilsizian VN (2008). Progresión a necrólisis epidérmica tóxica por uso de lamotrigina: A propósito de un caso. Rev. Argent. Dermatol. 89(3):188-192.

Arantes LB, Reis CS, Novaes AG, de Carvalho MR, Göttems LBD, Novaes MRCG (2017). Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals. An. Bras. Dermatol. 92(5):661-667.
Crossref

Barreto SM, Miranda JJ, Figueroa JP, Schmidt MI, Munoz S, Kuri-Morales PP, Silva JB Jr (2012). Epidemiology in Latin America and the Caribbean: current situation and challenges. Int. J. Epidemiol. 41(2):557-571.
Crossref

Bequignon E, Duong TA, Sbidian E, Valeyrie-Allanore L, Ingen-Housz-Oro S, Chatelin V, Coste A, Wolkenstein P, Chosidow O, Papon JF (2015). Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisEar, Nose, and Throat Description at Acute Stage and After Remission. JAMA Dermatol. 151(3):302-307.
Crossref

Blumenthal KG, Wickner PG, Lau JJ, Zhou L (2015). Stevens-Johnson syndrome and toxic epidermal necrolysis: A cross-sectional analysis of patients in an integrated allergy repository of a large healthcare system. J. Allergy Clin. Immunol. Pract. 3(2): 277-280.
Crossref

Bouvy JC, De Bruin ML, Koopmanschap MA (2015). Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Saf. 38(5):437-453.
Crossref

Bulisani ACP (2006). Síndrome de Stevens-Johnson e necrólise epidérmica tóxica em medicina intensiva. Rev. Bras. Ter. Intensiva. 18(3).
Crossref

Castana O, Rempelos G, Angiotos G, Apostopoulou C, Dimitrouli A, Alexakis D (2009). Stevens-Johnson Syndrome: a Case Report. Ann. Burns Fire Disasters 22(3):147-151.

Çekiç S, Canıtez Y, Sapan N (2016). Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience. Turk. Pediatr. Ars. 51(3):152-158.
Crossref

Chantaphakul H, Sanon T, Klaewsongkram J (2015). Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp. Ther. Med. 10(2):519-524.
Crossref

Das JK, Medhi J, Chakravart R, Soibam R (2011). Mucous membrane grafting for the post-Steven–Johnson syndrome symblepharon: A case report. Indian J. Ophthalmol. 59(3):231-233.
Crossref

Dominguez CD, Brice-o JF, Marin CB, Ospina CA (2012). Síndrome de Stevens Johnson asociado a fenitoína en una paciente colombiana con síndrome convulsivo focal. MÉDICAS UIS 245(2):155-162.

Ellender RP, Peters CW, Albritton HL, Garcia AJ, Kaye AD (2014). Clinical considerations for epidermal necrolysis. Ochsner. J. 14:413-417.

Falcão PGCB, Santos TS, Avelar RL, Antunes AA, Pita Neto IC, Dourado E (2008). Síndrome de Stevens-Johnson associada ao uso de antimicrobiano. Rev. Gaúcha. Odontol. 56(3): 337-340.

French LE (2006). Toxic Epidermal Necrolysis and Stevens Johnson Syndrome: Our Current Understanding. Allergol. Int. 55(1):9-16.
Crossref

Galvão TF, Pansani TSA, Harrad D (2015). Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiol. Serv. 24(2):335-342.
Crossref

Garcia JBS, Ferro LSG, Carvalho AB, Rocha RM, Souza LML (2010). Reação cutânea grave induzida por carbamazepina no tratamento da neuralgia pós-herpética: relato de caso. Rev. Bras. Anestesiol. 60(4):433-437.
Crossref

Hsieh HJ, Chan ALF, Lin SJ (2009). Stevens-Johnson Syndrome Induced by Combination of Imatinib and Allopurinol. Chemother. 55(4):197-199.
Crossref

Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016). Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J. Investig. Dermatol. 136(7):1387-1397.
Crossref

Jao J, Sturdevant M, Del Rio Martin J, Schiano T, Fiel MI, Huprikar S (2010). Nevirapine-Induced Stevens Johnson–Syndrome and Fulminant Hepatic Failure Requiring Liver Transplantation. Am. J. Transplant. 10(7):1713-1716.
Crossref

Kannenberg SMH, Jordaan HF, Koegelenberg CFN, Groote-Bidlingmaier FV, Visser WI (2012). Toxic epidermal necrolysis and Stevens–Johnson syndrome in South Africa: a 3-year prospective study. Q. J. Med. 105:839-846.
Crossref

Kaur S, Dogra A (2013). Toxic Epidermal Necrolysis Due to Concomitant Use of Lamotrigine and Valproic Acid. Ind. J. Dermatol. 58(5): 406.
Crossref

Kinoshita Y, Saeki H (2017). A review of toxic epidermal necrolysis management in Japan. Allergol Int. 66(1): 36-41.
Crossref

Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP (2014). Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J. Am. Acad. Dermatol. 71(5):941-947.
Crossref

Knight L, Todd G, Muloiwa R, Matjila M, Lehloenya RJ (2015). Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women. PLoS one 10(8):e0135501.
Crossref

Kuek A, Hazleman BL, Östör AJK (2007). Immune‐mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 83(978):251-260.
Crossref

Kumar PNS, Thomas B, Kumar K, Kumar S (2005). Stevens–Johnson syndrome–toxic epidermal necrolysis (SJS–TEN) overlap associated with carbamazepine use. Indian. J. Psychiatr. 47(2):121-123.
Crossref

Lebrun-Vignes B, Guy C, Jean-Pastor MJ, Gras-Champel V, Zenut M (2017). The French Network of Regional Centres of Pharmacovigilance and the French Investigators for Adverse Skin Reactions to Drugs. Is acetaminophen associated with a risk of Stevens–Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. Br. J. Clin. Pharmacol. pp. 331-338.

Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC (2012). The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J. Dermatol. 167:555-562.
Crossref

Lim VM, Do A, Berger TG, Nguyen AH, DeweeseJ, Malone JD, Jordan K, Hom F, Tuffanelli L, Fillari P, Siu S, Grossman R (2016). A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness. Burns 42(4):836-843.
Crossref

Martínez-Pérez JD, Caldevilla-Bernardo R, Perales-Pardo F, Pérez-Gómez (2012). Síndrome de Stevens-Johnson, a propósito de un caso de fiebre y erupción cutánea. Rev. Semergen. 38(4): 245-247.
Crossref

Mendonça RJ, Netto JC (2009). Aspectos Celulares Da Cicatrização. An. Bras. Dermatol. 84(3):257-262.
Crossref

Mockenhaupt M (2011). The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Rev. Clin. Immunol. 7(6):803-815.
Crossref

Mockenhaupt M, Hautreaktionen DS (2017). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. National Organization for Rare Disorders (NORD). Available at: 

View

Nagao-Dias AT, Barros-Nunes P, Coelho HLL, Solé D (2004). Reações alérgicas a medicamentos. J. Pediatr. 80(4):259-266.
Crossref

Owczarczyk-Saczonek A, Zdanowska N, Znajewska-Pander A, Placek W (2016). Stevens-Johnson syndrome in a patient with rheumatoid arthritis during long-term etanercept therapy. J. Dermatol. Case Rep. 10(1):14-16.
Crossref

Patel TK, Barvaliya MJ, Sharma D, Tripathi C (2013). A systematic review of the drug‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J. Dermatol. Venereol. Leprol. 79(3):389-398.
Crossref

Pereira JG (2012). Reações Adversas a Medicamentos. Secretaria de Ciência, Tecnologia e Insumo Estratégicos/MS-FTN. Available from: View.

Quinones HJ, Chavez V, Ángel J, Hernandez OB (2011). Síndrome de Stevens-Johnson: presentación de un caso. AMC 15(3):576-584.

Salama M, Lawrance IC (2009). Stevens Johnson Syndrome complicating adalimumab therapy in Crohn's disease. World J. Gastroenterol. 15(35):4449-4452.
Crossref

Schneider JA, Cohen PR (2017). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv. Ther. 34(6):1235-1244.
Crossref

Sotelo-Cruz N, Hurtado-Valenzuela JG, Rascón-Alcantar A (2005). Síndrome de Stevens-Johnson. Informe de 7 casos. Bol. Med. Hosp. Infant. Mex. 62(1):25-32.

Sun J, Liu J, Gong QL, Ding GZ, Ma LW, Zhang LC, Lu Y (2014). Stevens–Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China. Drug Des. Dev. Ther. 8:2539-2547.
Crossref

Sweileh WM (2017). Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 – 2015. Orphanet. J Rare Dis. 12:14.
Crossref

Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W (2013). Relationship Between the HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisA Systematic Review and Meta-analysis. JAMA Dermatol.149(9):1025-1032.
Crossref

Thong BYH (2013). Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective. Asia Pac. Allergy. 3(4):215-223.
Crossref

Trivedi BS, Darji NH, Malhotra SD, Patel PR (2017). Antiepileptic Drugs-induced Stevens-Johnson syndrome: A case Series. J. Basic Clin. Pharma. 8:42-44.
Crossref

United Nations (UN) (2016). Statistics Division. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. Available at: 

View

US National Institute of Health (NIH) (2014). Age filters. Available at: 

View. (Accessed 16 April 2016).

Verge C, Lucena MI, López-Torres E, Puche-García MJ, Fraga E, Romero-Gomez M, Andrade RJ (2006). Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs. World J. Gastroenterol. 12(31): 5078-5080.
Crossref

Walley T (2000). Davies Textbook of Adverse Drug Reactions. Postgrad. Med. J. 76(901):741.
Crossref

Wang L, Mei XL (2017). Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients. Chin. Med. J. 130(9):1062-1068.
Crossref

Williams RJ, Tse T, DiPiazza K, Zarin DA (2015). Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination. PLoS one 10(5): e0127242.
Crossref

Wong A, Malvestiti AA, Hafner MFS (2016). Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. Rev. Assoc. Med. Bras. 62(5):468-473.
Crossref

World Bank (2017). World Bank Open Data. Free and open access to global development data. Available at: 

View Accessed on 24 December 2017.

World Health Organization (WHO) (2017). Number of people (all ages) living with HIV Estimates by country. Available at: 

View Accessed on 20 December 2017.

Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, Ikezawa Z, Aihara M (2016). Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients - Treatment and outcome. Allergol Int. 65(1):74-81.
Crossref

Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, Park HW, Cho SH, Min KU, Kang HR (2016). Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS One 11(11):e0165933.
Crossref

Ye LP, Zhang C, Zhu QX (2016). The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens- Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis. PLoS ONE 11(11):e0167120.
Crossref

Zaidi M, Zaidi SK, Bhutto M, Umer MY (2017). Amoxycillin and clavulanic acid induced Stevens-Johnson syndrome: A case report. EXCLI J. 16:748-751.

Zaidi S, Saligram P, Ahmed S, Sonderp E, Sheikh K (2017). Expanding access to healthcare in South Asia. BMJ. 357:j1645.
Crossref

Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M (2017). Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 153(6):514-522.
Crossref